Last reviewed · How we verify
High Strength IDP-107
At a glance
| Generic name | High Strength IDP-107 |
|---|---|
| Sponsor | Dow Pharmaceutical Sciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris (PHASE2)
- A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Strength IDP-107 CI brief — competitive landscape report
- High Strength IDP-107 updates RSS · CI watch RSS
- Dow Pharmaceutical Sciences portfolio CI